Drug development for CNS disorders: strategies for balancing risk and reducing attrition (original) (raw)

• Pharmaceutical Research and Manufacturers of America (PhRMA). New Medicines in Development for Mental Illness. PhRMA web site [online], (2006).
• Pharmaceutical Research and Manufacturers of America (PhRMA). New Medicines in Development for Neurological Disorders. PhRMA web site [online], (2006).
• Ferri, C. P. et al. Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112–2117 (2005).
  PubMed PubMed Central Google Scholar
• Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711–715 (2004).
  CAS Google Scholar
• Tufts Center for the Study of Drug Development. Longer clinical times are extending time to market for new drugs in US. Tufts CSDD Impact Report 7, 1–4 (2005).
• Bornstein, N., Silvestrelli, G., Caso, V. & Parnetti, L. Arterial hypertension and stroke prevention: an update. Clin. Exp. Hypertens. 28, 317–326 (2006).
  PubMed Google Scholar
• Sato, A., Saruta, T. & Funder J. W. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens. Res. 29, 211–216 (2006).
  CAS PubMed Google Scholar
• Nitsch, R. M., Slack, B. E., Wurtman, R. J. & Growdon, J. H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258, 304–307 (1992).
  CAS PubMed Google Scholar
• Pangalos, M. N., Jacobsen, S. J. & Reinhart, P. H. Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the β-amyloid peptide. Biochem. Soc. Trans. 33, 553–558 (2005).
  CAS PubMed Google Scholar
• Dominguez, D. I. & De Strooper, B. Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease. Trends Pharmacol. Sci. 23, 324–330 (2002).
  CAS PubMed Google Scholar
• Zhang, L. et al. Characterization of the reconstituted γ-secretase complex from Sf9 cells co-expressing presenilin 1, nicastrin, aph-1a, and pen-2. Biochemistry 44, 4450–4457 (2005).
  CAS PubMed Google Scholar
• Marambaud, P. et al. A presenilin-1/γ-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J. 21, 1948–1956 (2002).
  CAS PubMed PubMed Central Google Scholar
• Roberds, S. L. et al. BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 10, 1317–1324 (2001).
  CAS PubMed Google Scholar
• Hong, L. et al. Crystal structure of memapsin 2 (β-secretase) in complex with an inhibitor OM00–3. Biochemistry 41, 10963–10967 (2002).
  CAS PubMed Google Scholar
• Booth, B. & Zemmel, R. Prospects for productivity. Nature Rev. Drug Discov. 3, 451–456 (2004).
  CAS Google Scholar
• Hornig, C. R. et al. CT contrast enhancement on brain scans and blood–CSF barrier disturbances in cerebral ischemic infarction. Stroke 16, 268–273 (1985).
  CAS PubMed Google Scholar
• Papadopoulos, C. M. et al. Dendritic plasticity in the adult rat following middle cerebral artery occlusion and Nogo-a neutralization. Cereb. Cortex 16, 529–536 (2006).
  PubMed Google Scholar
• Schenk, D. et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173–177 (1999).
  CAS PubMed Google Scholar
• Bard, F. et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med. 6, 916–919 (2000).
  CAS PubMed Google Scholar
• Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) 82, 239–259 (1991).
  CAS Google Scholar
• Akiyama, H. et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383–421 (2000).
  CAS PubMed PubMed Central Google Scholar
• Reddy, P. & Beal, M. Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res. Brain Res. Rev. 49, 618–632 (2005).
  CAS PubMed Google Scholar
• Kivipelto, M. et al. Apolipoprotein E ɛ4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann. Intern. Med. 137, 149–155 (2002).
  CAS PubMed Google Scholar
• Brunton, V. G. et al. Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior. Cancer Res. 65, 1335–1342 (2005).
  CAS PubMed Google Scholar
• Paul, R. et al. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nature Med. 7, 222–227 (2001).
  CAS PubMed Google Scholar
• Lebovitz, H. Diabetes: assessing the pipeline. Atheroscler. Suppl. 7, 43–49 (2006).
  PubMed Google Scholar
• Feinstein, D. L. et al. Peroxisome proliferator-activated receptor-γ agonists prevent experimental autoimmune encephalomyelitis. Ann. Neurol. 51, 694–702 (2002).
  CAS PubMed Google Scholar
• Heneka, M. T., Landreth, G. E. & Feinstein, D. L. Role for peroxisome proliferator-activated receptor-γ in Alzheimer's disease. Ann. Neurol. 49, 276 (2001).
  CAS PubMed Google Scholar
• Rosenzweig-Lipson, S. et al. Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503. Brain Res. 1073–1074, 240–251 (2006).
  PubMed Google Scholar
• Schechter, L. et al. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2, 590–611 (2005).
  PubMed PubMed Central Google Scholar
• Porter R. H. et al. A clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J. Pharmacol. Exp. Ther. 315, 711–721 (2005).
  CAS PubMed Google Scholar
• Miyamoto, S., Duncan, G. E., Marx, C. E. & Lieberman, J. A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10, 79–104 (2005).
  CAS PubMed Google Scholar
• Braff, D. L. L., G. A. . The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia. Dialogues Clin. Neurosci. 7, 125–135 (2005).
  PubMed PubMed Central Google Scholar
• Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30, 2752–2758 (1999).
• Lees, K. R. et al. NXY-059 for acute ischemic stroke. N. Engl. J. Med. 354, 588–600 (2006).
  CAS PubMed Google Scholar
• Ireland, R. Is NXY-059 beneficial in ischemic stroke? Nature Clin. Pract. Cardiovasc. Med. 3, 240–241 (2006).
  Google Scholar
• Fong, J. J. & Rhoney, D. H. NXY-059: review of neuroprotective potential for acute stroke. Ann. Pharmacother. 40, 461–471 (2006).
  CAS PubMed Google Scholar
• [No Authors Listed]. The Bitterest pill. Nature 444, 532–533 (2006).
• Leow, A. D. et al. Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage 31, 627–640 (2006).
  PubMed Google Scholar
• Schenk, D., Games, K. D. & McConlogue, L. The potential utility of transgenic mice harboring β-amyloid precursor protein. Neurobiol. Aging 16, 711–713 (1995).
  CAS PubMed Google Scholar
• Bloom, F. E. et al. Mouse models of human neurodegenerative disorders: requirements for medication development. Arch. Neurol. 62, 185–187 (2005).
  PubMed Google Scholar
• Harrison, S. M. et al. BACE1 (β-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes. Mol. Cell. Neurosci. 24, 646–55 (2003).
  CAS PubMed Google Scholar
• Laird, F. M. et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-β amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 25, 11693–11709 (2005).
  CAS PubMed PubMed Central Google Scholar
• Roher, A. E. & Kokjohn, T. A. Appraisal of AβPP transgenic mice as models for Alzheimer's disease amyloid cascade. Curr. Med. Chem. 3, 85–90 (2003).
  CAS Google Scholar
• Lehmann, H. E. & Ban, T. A. The history of the psychopharmacology of schizophrenia. Can. J. Psychiatry 42, 152–162 (1997).
  CAS PubMed Google Scholar
• Janssen, P. A., Niemegeers, C. J. & Schellekens, K. H. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data?I. 'Neuroleptic Activity Spectra' for rats. Arzneimittelforschung. 15, 104–117 (1965).
  CAS PubMed Google Scholar
• Costall, B., Naylor, R. J. & Nohria, V. Climbing behaviour induced by apomorphine in mice: a potential model for the detection of neuroleptic activity. Eur. J. Pharmacol. 50, 39–50 (1978).
  CAS PubMed Google Scholar
• Braff, D. L. & Geyer, M. A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry 47, 181–188 (1990).
  CAS PubMed Google Scholar
• Lipska, B. & Weinberger, D. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23, 223–239 (2000).
  CAS PubMed Google Scholar
• Cryan, J., Markou, A. & Lucki, I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 23, 238–245 (2002).
  CAS PubMed Google Scholar
• Rupniak, N. M. & Kramer, M. S. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol. Sci. 20, 485–490 (1999).
  CAS PubMed Google Scholar
• Herpfer, I. & Lieb, K. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 19, 275–293 (2005).
  CAS PubMed Google Scholar
• Ranga, K. & Krishnan, R. Clinical experience with substance P receptor (NK1) antagonists in depression. J. Clin. Psychiatry. 63 (Suppl. 11), 25–29 (2002).
  CAS PubMed Google Scholar
• Frank, R. & Hargreaves, R. Clinical biomarkers in drug discovery and development. Nature Rev. Drug Discov. 2, 566–280 (2003).
  CAS Google Scholar
• Nestler, E. et al. Preclinical models: Status of basic research in depression. Biol. Psychiatry 52, 503–528 (2002).
  PubMed Google Scholar
• Risch, N. & Botstein, D. A manic depressive history. Nature Genet. 12, 351–353 (1996).
  CAS PubMed Google Scholar
• Terwilliger, J. On the resolution and feasibility of genome scanning approaches. Adv. Genet. 42, 351–391 (2001).
  CAS PubMed Google Scholar
• Harrison, P. & Weinberger, D. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 10, 40–68 (2005).
  CAS PubMed Google Scholar
• Kamiya, A. et al. A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex: development. Nature Cell Biol. 7, 1167–1178 (2005).
  PubMed Google Scholar
• Rawlins, M. D. Cutting the cost of drug development? Nature Rev. Drug Discov. 3, 360–364 (2004).
  CAS Google Scholar
• Sheiner, L. Learning versus confirming in clinical drug development. Clin. Pharm. Ther. 61, 275–291 (1997).
  CAS Google Scholar
• Whalley, L., Deary, I., Appleton, C. & Starr, J. Cognitive reserve and the neurobiology of cognitive aging. Ageing Res. Rev. 3, 369–382 (2004).
  PubMed Google Scholar
• Winblad, B. & Poritis, N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int. J. Geriatr. Psychiatry 14, 135–146 (1999).
  CAS PubMed Google Scholar
• Rush, A. J. et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med. 354, 1231–1242 (2006).
  CAS PubMed Google Scholar
• Trivedi, M. H. et al. Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med. 354, 1243–1252 (2006).
  CAS PubMed Google Scholar
• Wolf, C. R. & Smith, G. Cytochrome P450 CYP2D6. IARC Sci. Publ. 148, 209–229 (1999).
  CAS Google Scholar
• Emilien, G., Ponchon, M., Caldas, C., Isacson, O. & Maloteaux, J. M. Impact of genomics on drug discovery and clinical medicine. Q. J. Med. 93, 391–423 (2000).
  CAS Google Scholar
• Poulsen, L. et al. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur. J. Clin. Pharmacol. 51, 289–295 (1996).
  CAS PubMed Google Scholar
• Defilippi, J. L. & Crismon, M. L. Drug interactions with cholinesterase inhibitors. Drugs Aging 20, 437–444 (2003).
  CAS PubMed Google Scholar
• Smeraldi, E. et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry 3, 508–511 (1998).
  CAS PubMed Google Scholar
• Lane, H. Y. et al. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am. J. Psychiatry 159, 1593–1595 (2002).
  PubMed Google Scholar
• Roses, A. D. et al. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics J. 7, 10–28 (2007).
  CAS PubMed Google Scholar
• Tsuang, M. T. & Faraone, S. V. Genetics of Alzheimer's disease. J. Formos. Med. Assoc. 95, 733–740 (1996).
  CAS PubMed Google Scholar
• Klimas, M. Positron emission tomography and drug discovery: contributions to the understanding of pharmacokinetics, mechanism of action and disease state characterization. Mol. Imaging Biol. 4, 311–337 (2002).
  PubMed Google Scholar
• Dawson, D. A., Wadsworth, G. & Palmer, A. M. A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke. Brain Res. 892, 344–350 (2001).
  CAS PubMed Google Scholar
• Matsuoka, Y. et al. An Aβ sequestration approach using non-antibody Aβ binding agents. Curr. Alzheimer Res. 2, 265–268 (2005).
  CAS PubMed Google Scholar
• Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486–489 (2003).
  CAS PubMed Google Scholar
• Motter, R. et al. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38, 643–648 (1995).
  CAS PubMed Google Scholar
• Lewczuk, P. et al. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: Original data and review of the literature. J. Mol. Neurosci. 23, 115–122 (2004).
  CAS PubMed Google Scholar
• Pratico, D. & Sung, S. Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. J. Alzheimers Dis. 6, 171–175 (2004).
  CAS PubMed Google Scholar
• Renna, M., Handy, J. & Shah, A. Low baseline Bispectral Index of the electroencephalogram in patients with dementia. Anesth. Analg. 96, 1380–1385 (2003).
  PubMed Google Scholar
• LeBlanc, J., Dasta, J. & Kane-Gill, S. Role of the bispectral index in sedation monitoring in the ICU. Ann. Pharmacother. 40, 490–500 (2006).
  PubMed Google Scholar
• Herrmann, C. & Demiralp, T. Human EEG γ oscillations in neuropsychiatric disorders. Clin. Neurophysiol. 116, 2719–2733 (2005).
  CAS PubMed Google Scholar
• Mohs, R. et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis. Assoc. Disord. 11 (Suppl. 2), 13–21 (1997).
  Google Scholar
• Solomon, P. et al. Classical conditioning in patients with Alzheimer's disease: a multiday study. Psychol. Aging 10, 248–254 (1995).
  CAS PubMed Google Scholar
• Skelton, R., Ross, S., Nerad, L. & Livingstone, S. Human spatial navigation deficits after traumatic brain injury shown in the arena maze, a virtual Morris water maze. Brain Inj. 20, 189–203 (2006).
  PubMed Google Scholar
• Pariente, J. et al. Alzheimer's patients engage an alternative network during a memory task. Ann Neurol 58, 870–879 (2005).
  PubMed Google Scholar
• Frank, R. A. et al. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol. Aging 24, 521–536 (2003).
  PubMed Google Scholar
• Klunk, W. et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-β in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 25, 10598–10606 (2005).
  CAS PubMed PubMed Central Google Scholar
• Kung, M., Zhuang, Z., Hou, C. & Kung, H. Development and evaluation of iodinated tracers targeting amyloid plaques for SPECT imaging. J. Mol. Neurosci. 24, 49–53 (2004).
  CAS PubMed Google Scholar
• Versijpt, J. et al. Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study. Eur. Neurol. 50, 39–47 (2003).
  CAS PubMed Google Scholar
• Johnson, N. et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 234, 851–859 (2005).
  PubMed Google Scholar
• Han, S., Nestor, P. & Wible, C. fMRI of lexical-semantic priming in a chronic schizophrenia patient. Appl. Neuropsychol. 13, 51–57 (2006).
  PubMed Google Scholar
• Chudasama, Y. & Robbins, T. W. Dopaminergic modulation of visual attention and working memory in the rodent prefrontal cortex. Neuropsychopharmacology 29, 1628–1636 (2004).
  CAS PubMed Google Scholar
• Spinelli, S. et al. Performance of the marmoset monkey on computerized tasks of attention and working memory. Brain Res. Cogn. Brain Res. 19, 123–137 (2004).
  PubMed Google Scholar
• Spinelli, S. et al. Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys. Psychopharmacology (Berl.) 179, 292–302 (2005).
  CAS Google Scholar
• Olson, H. et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56–67 (2000).
  CAS PubMed Google Scholar
• Huby, R. & Tugwood, J. D. Gene expression profiling for pharmaceutical safety assessment. Expert Opin. Drug Metab. Toxicol. 1, 247–260 (2005).
  CAS PubMed Google Scholar
• Drazen, J. M. Patients at risk. N. Engl. J. Med. 353, 417 (2005).
  CAS PubMed Google Scholar
• O'Toole, M. et al. Risk factors associated with β-amyloid(1–42) immunotherapy in preimmunization gene expression patterns of blood cells. Arch. Neurol. 62, 1531–1536 (2005).
  PubMed Google Scholar
• Davies, P. & Maloney, A. J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2, 1403 (1976).
  CAS PubMed Google Scholar
• Bowen, D. M., Smith, C. B., White, P. & Davison, A. N. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99, 459–496 (1976).
  CAS PubMed Google Scholar
• Perry, E. K., Perry, R. H., Blessed, G. & Tomlinson, B. E. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1, 189 (1977).
  CAS PubMed Google Scholar
• Whitehouse, P. J. et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215, 1237–1239 (1982).
  CAS PubMed Google Scholar
• Bartus, R. T., Dean, R. L. 3rd, Beer, B. & Lippa, A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408–414 (1982).
  CAS PubMed Google Scholar
• Ferrante, R. J., Kowall, N. W. & Richardson, E. P. Jr . Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J. Neurosci. 11, 3877–3887 (1991).
  CAS PubMed PubMed Central Google Scholar
• Francis, P. T. et al. Antemortem measurements of neurotransmission: possible implications for pharmacotherapy of Alzheimer's disease and depression. J. Neurol. Neurosurg. Psychiatry 56, 80–84 (1993).
  CAS PubMed PubMed Central Google Scholar
• Schechter, L. et al. Lecozotan (SRA-333): A selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J. Pharmacol. Exp. Ther. 314, 1274–1289 (2005).
  CAS PubMed Google Scholar
• King, M. V. et al. 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation — an effect sensitive to NMDA receptor antagonism. Neuropharmacology 47, 195–204 (2004).
  CAS PubMed Google Scholar
• Komater, V. A. et al. H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization. Psychopharmacology (Berl.) 167, 363–372 (2003).
  CAS Google Scholar
• Selkoe, D. J. & Schenk, D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43, 545–584 (2003).
  CAS PubMed Google Scholar
• St George-Hyslop, P. H. & Petit, A. Molecular biology and genetics of Alzheimer's disease. C. R. Biol. 328, 119–130 (2005).
  CAS PubMed Google Scholar
• Podlisny, M. B., Lee, G. & Selkoe, D. J. Gene dosage of the amyloid β precursor protein in Alzheimer's disease. Science 238, 669–671 (1987).
  CAS PubMed Google Scholar
• DeMattos, R. B. et al. ApoE and clusterin cooperatively suppress Aβ levels and deposition. Evidence that ApoE regulates extracellular Aβ metabolism in vivo. Neuron 41, 193–202 (2004).
  CAS PubMed Google Scholar
• Klein, W. L. Aβ toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 41, 345–352 (2002).
  CAS PubMed Google Scholar
• Lesne, S. et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352–357 (2006).
  CAS PubMed Google Scholar
• Walsh, D. M. et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535–539 (2002).
  CAS PubMed Google Scholar
• Jacobsen, J. S., Reinhart, P. & Pangalos, M. N. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. NeuroRx 2, 612–626 (2005).
  PubMed PubMed Central Google Scholar
• Carlsson, A., Jonason, J., Lindqvist, M. & Fuxe, K. Demonstration of extraneuronal 5-hydroxytryptamine accumulation in brain following membrane-pump blockade by chlorimipramine. Brain Res. 2, 456–460 (1969).
  Google Scholar
• Goodwin, F. & Bunney, W. J. Depressions following reserpine: A reevaluation. Semin. Psychiatry 3, 435–448 (1971).
  CAS PubMed Google Scholar
• Hirschfeld, R. History and evolution of the monoamine hypothesis of depression. J. Clin. Psychiatry 61, 4–6 (2000).
  CAS PubMed Google Scholar
• Artigas, F., Romero, L., de Montigny, C. & Blier, P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci. 19, 378–383 (1996).
  CAS PubMed Google Scholar
• Merikangas, K. & Risch, N. Will the genomics revolution revolutionize psychiatry? Am. J. Psychiatry 160, 625–635 (2003).
  PubMed Google Scholar
• Hasler, G., Drevets, W., Manji, H. & Charney, D. Discovering endophenotypes for major depression. Neuropsychopharmacology 29, 1765–1781 (2004).
  CAS PubMed Google Scholar
• Kinney, D. et al. Season of birth and obstetrical complications in schizophrenics. J. Psychiatr. Res. 28, 499–509 (1994).
  CAS PubMed Google Scholar
• Kelly, B., Lane, A., Agartz, I., Henriksson, K. & McNeil, T. Craniofacial dysmorphology in Swedish schizophrenia patients. Acta Psychiatr. Scand. 111, 202–207 (2005).
  CAS PubMed Google Scholar
• Sheline, Y., Gado, M. & Kraemer, H. Untreated depression and hippocampal volume loss. Am. J Psychiatry 160, 1516–1518 (2003).
  PubMed Google Scholar
• Sheline, Y., Wang, P., Gado, M., Csernansky, J. & Vannier, M. Hippocampal atrophy in recurrent major depression. Proc. Natl Acad. Sci. USA 93, 3908–3913 (1996).
  CAS PubMed PubMed Central Google Scholar
• Malberg, J., Eisch, A., Nestler, E. & Duman, R. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 20, 9104–9110 (2000).
  CAS PubMed PubMed Central Google Scholar